SANOFI

Press Release
AUSTRALIA
FOR IMMEDIATE RELEASE

Sanofi Genzyme partners with Invitae on new program to support greater access to genetic testing

Sydney – 4 May 2021 - Sanofi Genzyme has partnered with leading medical genetics company, Invitae, to sponsor Australia's first no-charge genetic testing programs for patients suspected by their clinician of having a genetic cause for their cardiac or neuromuscular signs and symptoms.

With Sanofi Genzyme's support, Invitae's *Detect* Cardiomyopathy and Arrhythmia program and Invitae's *Detect* Muscular Dystrophy program will be made available to specialist physicians who are working to understand if their patients' clinical symptoms are driven by an underlying genetic cause. The programs provide access to clinical support for consultation regarding result interpretation and family management.

Sanofi Genzyme Australia and New Zealand Head of Medical, Dr Paul King, said many Australians who are living with a rare disease still face unreasonably long journeys to diagnosis.

"Unfortunately, diagnostic delay is still very common. Recent statistics published from Rare Voices Australia tell us that, for up to 30% of Australians who are living with a rare disease, their diagnostic journey took more than five years[1]," he said.

"This lack of diagnosis can mean years of uncertainty, anxiety, depression as well as poor control of a progressive disease.

"Sanofi Genzyme already offers no-charge access to diagnostic testing for patients suspected of having Lysosomal Storage Disorders, such as Fabry and Pompe disease, and supports screening initiatives in high risk patients to assist clinicians in their diagnosis. We also know that genetic panel testing for high risk patients is one of the best tools clinicians have for earlier diagnosis.

"We hope that this initiative to offer no-charge access to more of Invitae's *Detect* programs will speed up diagnosis and end the uncertainty leading to better health outcomes for more Australian patients."

"Genetic testing can provide essential health information, especially for these difficult-to-diagnose conditions for which Invitae's *Detect* programs are designed. With access to a

molecular diagnosis, patients can get faster access to available therapies or clinical trials," said Robert Nussbaum, M.D., chief medical officer of Invitae. "We're proud to partner with Sanofi Genzyme to make genetic testing more accessible to everyone and to make it easier for people living in Australia to receive testing and obtain the care they need."

For more information on Fabry disease you can visit Fabry Australia: www.fabry.com.au.

For more information on Pompe disease you can visit the Australian Pompe Association: www.australianpompe.org.au.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Media Relations Contact
Name: Amy O'Hara
Position: Communications Manager, Sanofi Australia
Tel.: 0417 861 984
Email: Amy.O-Hara@sanofi.com

References

1. Rare Voices Australia, What is a rare disease, available at www.rarevoices.org.au Accessed April 2021